Global road injuries have fallen since 1990 but still cause many deaths and serious harm, especially in poorer countries, so MS patients should know simple safety and post-crash care steps.
The study counted road traffic crashes around the world from 1990 to 2023 and found 50.9 million crashes that caused injury and 1.34 million deaths in 2023. Overall, the number of injuries and deaths per person went down since 1990, but some countries improved much more than others. Poorer countries had far more deaths per 100,000 people than richer countries, which means crashes are more likely to be deadly where care and roads are worse. Men aged 10–39 had the most deaths from road crashes, making it a top cause of death in that group. The study says better road design, stronger safety rules, safer cars, and faster emergency care after crashes can prevent many of these injuries and deaths.
MS patients and caregivers should care because people with MS can be more vulnerable after a crash — for example, weaker muscles, balance problems, or slower healing can make recovery harder. Think of it like having a fragile load in a box: if the box is dropped, the items inside get hurt more easily; MS can make the 'items' (your body) more likely to suffer long-term harm. Caregivers and families benefit from knowing safer travel habits, like planning routes with better roads, avoiding busy times, and making sure seatbelts and head supports fit well. Health providers and rehabilitation teams can use these findings to push for faster and better post-crash care, which helps people with MS recover more fully. Communities and planners can also help by improving sidewalks, street crossings, and transport options so people with mobility problems travel more safely.
The study looks at trends across whole countries, so it cannot tell you exactly how risky one specific street or trip is. Data quality varies between places, so counts may be less accurate in low-income areas where reporting is weaker. The study shows broad patterns and ideas for prevention, but it does not test specific MS treatments or give medical advice for individual patients.
AI-generated summary — for informational purposes only, not medical advice
12/31/2026
Learn how certain gut bacteria can worsen MS symptoms and what this means for treatment and daily li
Read More12/31/2026
Researchers found consistent gut bacteria differences in MS tied to disease type, treatment response
Read More9/1/2026
A small study found Ma/Ma2 antibodies can cause nerve-only symptoms often linked to cancer; testing
Read More9/1/2026
Long-term study shows ravulizumab greatly reduced relapses in AQP4+ NMOSD over 3+ years with expecte
Read More9/1/2026
Even without common antibodies, NMOSD can be severe and relapsing; early maintenance immune treatmen
Read More7/21/2026
Timing gaps in MS registries can make treatments seem better or worse. This study shows bias affects
Read MoreWhether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like The Lancet. Public health often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.
However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.
By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.